Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery

Assessment of the rapid effect of dupilumab in two cases of severe asthma comorbid with recurrent eosinophilic chronic rhinosinusitis after endoscopic sinus surgery

Abstract Dupilumab, a human monoclonal antibody against interleukin‐4 (IL‐4) and IL‐13, has been approved for treating severe asthma and eosinophilic chronic rhinosinusitis (ECRS). Patients with ECRS are often candidates for endoscopic sinus surgery (ESS). However, a considerable number of patients...

Full description

Bibliographic Details
Main Authors: Yoshiro Kai, Masanori Yoshikawa, Masayuki Matsuda, Atsuhiko Fukuoka, Yukio Fujita, Motoo Yamauchi, Shigeo Muro
Format: Article
Language:English
Published: Wiley 2021-08-01
Series:Respirology Case Reports
Subjects:
Asthma
dupilumab
IL‐4
IL‐13
rhinosinusitis
Online Access:https://doi.org/10.1002/rcr2.804

Internet

https://doi.org/10.1002/rcr2.804

Similar Items